113502-52-6

Basic information

• Product Name: 1-Keto Ketorolac
• Synonyms: 1-Keto Ketorolac;Ketorolac Related Compound C (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-one);5-Benzoyl-2,3-dihydro-1H-pyrrolizin-1-one;Ketorolac EP IMpurity B;Ketorolac Related CoMpound C;5-benzoyl-2,3-dihydropyrrolizin-1-one
• CAS NO: 113502-52-6
• Molecular Formula: C14H11NO2
• Molecular Weight: 225.24264
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals
• Mol File: 113502-52-6.mol

Chemical Properties

• Boiling Point: 427.9±33.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• PKA: -11.95±0.20(Predicted)
• CAS DataBase Reference: 1-Keto Ketorolac(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Keto Ketorolac(113502-52-6)
• EPA Substance Registry System: 1-Keto Ketorolac(113502-52-6)

Safety Data

• Hazardous Substances Data: 113502-52-6(Hazardous Substances Data)

Usage

Uses

Ketorolac impurity.

Upstream product

• 74103-06-3 Ketorolac 
• 77-86-1 2-amino-2-hydroxymethyl-1,3-propanediol 

Relevant articles and documents

FeCl3-catalyzed oxidative decarboxylation of aryl/heteroaryl acetic acids: Preparation of selected API impurities

There is an ever-increasing demand for impurity compounds for use in impurity profiling as regulatory agencies seek information during registration. Herein, we report the FeCl3-catalyzed oxidative decarboxylation of aryl- and heteroaryl acetic acids to the corresponding carbonyl compounds. A variety of useful aldehydes and ketones were prepared in a simple one-pot transformation by employing an environmentally benign, low-cost, and readily available iron salt. The utility of this method has been demonstrated by preparing five valuable API impurities including a multi-gram-scale synthesis of ketorolac impurity B for the first time. This journal is

Approaches for improving the stability of ketorolac in powder blends

Methods for improving the stability of ketorolac powder blends under elevated humidity and temperature conditions were investigated. The approaches that were examined for potentially increasing the stability of ketorolac were varying the ketorolac salt form, altering the excipient ratios, and adding antioxidants or pH modifiers to the formulation. The ketorolac powder blends were stored for 3 months at 75% relative humidity (RH) and 40, 50, and 60 °C. The results showed that the salt form of ketorolac had a large impact on stability after 3 months of storage at 50 °C/75% RH. The calcium salt powder blend and the free acid powder blend exhibited only 0.2% and 0.5% drug loss, respectively, whereas the tromethamine salt powder blend showed a 10.2% drug loss. Varying the ratios of lactose, microcrystalline cellulose, and croscarmellose sodium in the powder blends of ketorolac tromethamine showed that croscarmellose sodium and microcrystalline cellulose destabilized ketorolac. Addition of propyl gallate (1% w:w) to ketorolac tromethamine powder blends increased the stability of the ketorolac significantly. Addition of pH modifiers caused a modest improvement in the stability of ketorolac.